Concord Biotech (CONCORDBIO) | Stock Overview & Key Data
Concord Biotech Performance Comparison
Stock Range
Today's Range
Low: ₹1,479.90
High: ₹1,611.40
on August 11, 2025
52 Week Range
Low: ₹1,345.00
High: ₹2,664.00
on May 9, 2025
on September 20, 2024
All-Time High: ₹2,664.00 on September 16, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR167.4B
EPS
35.48
P/E Ratio (TTM)
45.04
Forward P/E
29.30
P/B Ratio
9.22
PEG Ratio
N/A
Div. Yield
0.44%
ROE
22.26%
Beta
N/A
Debt to Equity
0.16
Financial Highlights
Profitability
Gross Margin
70.11%
Operating Margin
40.90%
Profit Margin
30.97%
Returns and Earnings
Return on Assets (TTM)
15.13%
Return on Equity (TTM)
22.26%
EBITDA
INR5.5B
Net Income (TTM)
INR3.7B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR114.71
Quarterly Revenue Growth (YoY)
34.80%
Quarterly Earnings Growth (YoY)
47.80%
Dividend Information
Last 12-Month Dividend
₹8.75
Current Dividend Yield
0.44%
3-Year Average Dividend Yield
0.56%
3-Year Average Annual Dividend
₹2.92
3-Year Total Dividends
₹8.75
Ex-Dividend Date
June 21, 2024
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Concord Biotech CONCORDBIO | 167.44B Mid-cap | -8.20% | -10.88% | 4.92% | -28.51% | -25.63% | 2.85% | 69.50% | 69.50% |
| Biocon BIOCON | 456.09B Large-cap | -10.38% | -7.04% | 2.62% | -8.96% | -6.90% | 1.90% | 10.35% | -13.10% |
| OneSource Specialty ONESOURCE | 216.76B Large-cap | 1.94% | -5.48% | 18.19% | 22.64% | 10.61% | 10.61% | 10.61% | 10.61% |
| Blue Jet Healthcare BLUEJET | 139.66B Mid-cap | 1.11% | -8.20% | 11.31% | -0.69% | 39.42% | 69.26% | 106.52% | 106.52% |
| Supriya Lifescience SUPRIYA | 53.00B Mid-cap | 0.14% | -6.62% | 3.08% | -9.09% | -13.05% | 46.20% | 85.49% | 35.98% |
| Dishman Carbogen DCAL | 36.69B Small-cap | -3.47% | -8.84% | 27.79% | -2.26% | -17.23% | 22.14% | 106.15% | 27.13% |
Ownership & Short Interest
Insider Ownership
74.83%
Institutional Ownership
13.21%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
76K
Average 90-Day Volume
148K
Concord Biotech Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Concord Biotech would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is CONCORDBIO's 52-week high and low?
- In the last 52 weeks, Concord Biotech reached a high of ₹2,664.00 (on September 20, 2024) and a low of ₹1,345.00 (on May 9, 2025).
- What is the market cap and P/E ratio for CONCORDBIO?
- Curious about Concord Biotech's size and valuation? Its market capitalization stands at 167.44B. When it comes to valuation, the P/E ratio (trailing twelve months) is 45.04, and the forward P/E (looking ahead) is 29.30.
- Does CONCORDBIO pay dividends? If so, what's the yield?
- Yes, Concord Biotech is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.44%, and the company has paid an average of ₹2.92 per share annually over the past 3 years.
- Who are Concord Biotech's main competitors or similar companies to consider before investing?
When looking at Concord Biotech, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Biocon
BIOCON456.09B Healthcare Biotechnology 1.90% 10.35% OneSource Specialty
ONESOURCE216.76B Healthcare Biotechnology 10.61% 10.61% Blue Jet Healthcare
BLUEJET139.66B Healthcare Biotechnology 69.26% 106.52% Supriya Lifescience
SUPRIYA53.00B Healthcare Biotechnology 46.20% 85.49% Dishman Carbogen
DCAL36.69B Healthcare Biotechnology 22.14% 106.15% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Concord Biotech Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Concord Biotech's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 22.26%, the Debt to Equity ratio from the most recent quarter is 0.16, and its Gross Profit Margin stands at 70.11%.
- What is the recent revenue and earnings growth for CONCORDBIO?
- Looking at Concord Biotech's growth, its revenue over the trailing twelve months (TTM) was INR12B. Compared to the same quarter last year (YoY), quarterly revenue grew by 34.80%, and quarterly earnings saw a YoY growth of 47.80%.
- How much of CONCORDBIO stock is held by insiders and institutions?
- Wondering who owns Concord Biotech stock? Company insiders (like executives and directors) hold about 74.83% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 13.21%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.